Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Bradley Theodore Hyman, M.D., Ph.D.

Co-Author

This page shows the publications co-authored by Bradley Hyman and Joseph Locascio.
Connection Strength

1.098
  1. Association between a-synuclein blood transcripts and early, neuroimaging-supported Parkinson's disease. Brain. 2015 Sep; 138(Pt 9):2659-71.
    View in: PubMed
    Score: 0.163
  2. A Luminex assay detects amyloid ß oligomers in Alzheimer's disease cerebrospinal fluid. PLoS One. 2013; 8(7):e67898.
    View in: PubMed
    Score: 0.142
  3. Preservation of neuronal number despite age-related cortical brain atrophy in elderly subjects without Alzheimer disease. J Neuropathol Exp Neurol. 2008 Dec; 67(12):1205-12.
    View in: PubMed
    Score: 0.103
  4. Plasma amyloid beta-protein and C-reactive protein in relation to the rate of progression of Alzheimer disease. Arch Neurol. 2008 Jun; 65(6):776-85.
    View in: PubMed
    Score: 0.100
  5. Predictors of the importance of everyday preferences for older adults with cognitive impairment. Int Psychogeriatr. 2021 Jan 18; 1-8.
    View in: PubMed
    Score: 0.060
  6. beta-site APP cleaving enzyme mRNA expression in APP transgenic mice: anatomical overlap with transgene expression and static levels with aging. Am J Pathol. 2001 Jan; 158(1):173-7.
    View in: PubMed
    Score: 0.060
  7. ß-Glucocerebrosidase activity in GBA-linked Parkinson disease: The type of mutation matters. Neurology. 2020 08 11; 95(6):e685-e696.
    View in: PubMed
    Score: 0.057
  8. Differences in Assessment of Everyday Preferences Between People With Cognitive Impairment and Their Care Partners: The Role of Neuropsychiatric Symptoms. Am J Geriatr Psychiatry. 2020 10; 28(10):1070-1078.
    View in: PubMed
    Score: 0.056
  9. Lack of independent associations of apolipoprotein E promoter and intron 1 polymorphisms with Alzheimer's disease. Neurosci Lett. 1999 Sep 17; 272(3):155-8.
    View in: PubMed
    Score: 0.054
  10. Apolipoprotein E genotype does not influence rates of cognitive decline in Alzheimer's disease. Neurology. 1996 Aug; 47(2):444-8.
    View in: PubMed
    Score: 0.044
  11. Clinical and pathological correlates of apolipoprotein E epsilon 4 in Alzheimer's disease. Ann Neurol. 1996 Jan; 39(1):62-70.
    View in: PubMed
    Score: 0.042
  12. Subjective cognitive concerns and neuropsychiatric predictors of progression to the early clinical stages of Alzheimer disease. Am J Geriatr Psychiatry. 2014 Dec; 22(12):1642-51.
    View in: PubMed
    Score: 0.037
  13. Regional cortical thinning and cerebrospinal biomarkers predict worsening daily functioning across the Alzheimer's disease spectrum. J Alzheimers Dis. 2014; 41(3):719-28.
    View in: PubMed
    Score: 0.037
  14. Unrecognized vitamin D3 deficiency is common in Parkinson disease: Harvard Biomarker Study. Neurology. 2013 Oct 22; 81(17):1531-7.
    View in: PubMed
    Score: 0.036
  15. Effects of simvastatin on cholesterol metabolism and Alzheimer disease biomarkers. Alzheimer Dis Assoc Disord. 2010 Jul-Sep; 24(3):220-6.
    View in: PubMed
    Score: 0.029
  16. Imaging amyloid deposition in Lewy body diseases. Neurology. 2008 Sep 16; 71(12):903-10.
    View in: PubMed
    Score: 0.025
  17. Association of homocysteine with plasma amyloid beta protein in aging and neurodegenerative disease. Neurology. 2005 Nov 08; 65(9):1402-8.
    View in: PubMed
    Score: 0.021
  18. Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels. Arch Neurol. 2003 Jul; 60(7):958-64.
    View in: PubMed
    Score: 0.018
  19. Glutamate receptor dysregulation in the hippocampus of transgenic mice carrying mutated human amyloid precursor protein. Neurobiol Dis. 2001 Feb; 8(1):90-102.
    View in: PubMed
    Score: 0.015
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.